AI is transforming drug discovery, clinical trial management, and regulatory submissions — but every AI decision in a GxP environment must be validated, traced, and defensible to the FDA. A single unexplainable AI output in a regulatory submission can delay a drug application by years. Varman provides the audit infrastructure that makes AI-assisted drug development FDA-submittable.
AI agents introduce novel attack surfaces and compliance blind spots. These are the vectors your security and compliance teams must address now.
AI agents analyzing clinical trial endpoints, identifying adverse events, and processing patient-reported outcomes must operate under 21 CFR Part 11 electronic records controls. Untracked AI contributions to clinical data — even in analysis and reporting phases — create audit findings that delay or derail regulatory submissions.
Computational models predicting drug-drug interactions, ADMET properties, and safety signals must maintain validated performance across the full development lifecycle. Model drift that degrades prediction accuracy can result in missed safety signals during preclinical development — leading to Phase III failures or post-market safety withdrawals.
FDA reviewers now routinely request complete documentation of AI contributions to NDA and BLA submissions — including training data provenance, model validation records, and change history. Submissions that cannot answer these questions face Complete Response Letters that can delay approval by 12-24 months.
Drug discovery AI agents operating on proprietary compound libraries, synthesis routes, and biological assay data represent high-value IP. Without access controls and data lineage tracking across AI workflows, pharmaceutical trade secrets can be inadvertently exposed through model training data, API calls to external providers, or cross-project data contamination.
Three integrated pillars — Observe, Govern, Secure — working in concert to give Pharmaceutical & Life Sciences teams complete AI agent control.
Varman maps directly to the regulatory frameworks governing AI in Pharmaceutical & Life Sciences. Deploy with confidence knowing every requirement is addressed.
Electronic records and electronic signatures regulation applies to all AI-generated records in FDA-regulated environments.
Good Practice guidelines (GMP, GCP, GLP) require validation, audit trails, and change control for computerized systems including AI.
International Council for Harmonisation Good Clinical Practice guidelines govern AI contributions to clinical trial data collection and analysis.
European Medicines Agency reflection paper on AI in the lifecycle of medicines requires transparency, validation, and post-market monitoring.
AI systems used in medical device and pharmaceutical applications are classified as high-risk under the EU AI Act — requiring conformity assessment.
Real results from Pharmaceutical & Life Sciences organizations deploying Varman across their AI agent infrastructure.
The FDA is scrutinizing AI contributions to drug applications like never before. Build your AI governance infrastructure now — before your NDA submission — and transform regulatory review from a risk into a competitive differentiator.